Canada - English - Health Canada

apotex inc - bosentan (bosentan monohydrate) - tablet - 125.0mg - bosentan (bosentan monohydrate) 125.0mg - vasodilating agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 64.542 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: silicon dioxide; methylcellulose; crospovidone; poloxamer; macrogol 8000; titanium dioxide; iron oxide red; hyprolose; hypromellose; magnesium stearate; iron oxide yellow - bosentan is indicated for the treatment of: ? idiopathic pulmonary arterial hypertension; ? familial pulmonary arterial hypertension; ? pulmonary arterial hypertension associated with scleroderma; or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 129.083 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; iron oxide yellow; crospovidone; poloxamer; silicon dioxide; iron oxide red; hypromellose; hyprolose; magnesium stearate; methylcellulose - bosentan is indicated for the treatment of: ? idiopathic pulmonary arterial hypertension; ? familial pulmonary arterial hypertension; ? pulmonary arterial hypertension associated with scleroderma; or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: glycerol dibehenate; magnesium stearate; pregelatinised maize starch; sodium starch glycollate type a; maize starch; povidone; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; maize starch; povidone; glycerol dibehenate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: glycerol dibehenate; magnesium stearate; maize starch; sodium starch glycollate type a; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms